analyst
SP
NASDAQ · SPRB
Spruce Biosciences, Inc.
Healthcare · Biotechnology
$55.17
Down-$1.69 (-2.96%)
Updated Sep 16, 2026, 10:24 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 51.65M
- P/E ratio
- -1.12
- Dividend yield
- 0.00%
- 52-week range
- $7.26 – $240.00
- Volume
- 110.11K
- Avg. volume
- 571.26K
Price performance
SPRB price history
1M range · 20 trading sessions · Daily adjusted prices
SPRB closed at $55.17 after 20 trading sessions, up 4.39% for the selected period.
- Last close
- $55.17
- Period change
- +4.39%
- Period low
- $51.58
- Period high
- $63.40
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $55.99 | $56.36 | $54.51 | $55.165 | 110.11K |
| Sep 14, 2026 | $53.28 | $57.55 | $52.66 | $56.85 | 102.62K |
| Sep 11, 2026 | $54.78 | $56.08 | $53.09 | $53.70 | 88.51K |
| Sep 10, 2026 | $55.61 | $57.50 | $54.03 | $54.35 | 118.76K |
| Sep 9, 2026 | $58.52 | $59.01 | $55.7001 | $55.74 | 96.36K |
| Sep 8, 2026 | $57.39 | $60.51 | $56.60 | $59.09 | 193.05K |
| Sep 4, 2026 | $57.37 | $58.19 | $56.57 | $57.93 | 104.95K |
| Sep 3, 2026 | $59.76 | $60.315 | $57.30 | $57.71 | 116.62K |
| Sep 2, 2026 | $56.52 | $60.13 | $56.52 | $59.67 | 268.14K |
| Sep 1, 2026 | $58.01 | $58.05 | $55.34 | $55.60 | 58.13K |
| Aug 31, 2026 | $60.54 | $60.90 | $57.575 | $58.97 | 44.94K |
| Aug 28, 2026 | $62.115 | $62.98 | $59.895 | $60.78 | 39.96K |
| Aug 27, 2026 | $62.00 | $63.56 | $60.55 | $63.30 | 80.3K |
| Aug 26, 2026 | $64.50 | $64.50 | $60.46 | $61.48 | 91.77K |
| Aug 25, 2026 | $58.82 | $64.15 | $58.00 | $63.40 | 147.3K |
| Aug 24, 2026 | $53.04 | $58.92 | $51.16 | $58.65 | 138.81K |
| Aug 21, 2026 | $52.48 | $53.00 | $49.03 | $51.58 | 62.31K |
| Aug 20, 2026 | $52.83 | $52.89 | $50.50 | $51.985 | 21.64K |
| Aug 19, 2026 | $54.18 | $54.93 | $52.02 | $52.96 | 88.35K |
| Aug 18, 2026 | $51.305 | $53.95 | $50.80 | $52.845 | 71.41K |
Latest SPRB news
The latest Smart Investors Daily articles mentioning SPRB.
Stock researchCompany · Overview
SPRB research
Overview
Company profile and research snapshot.
Company profile
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The pipeline products of the company include Tralesinidase Alfa (TA-ERT), and Tildacerfont/ Cortibon, a Companion Diagnostic, developed in partnership with HMNC Brain Health.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $209.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Guggenheim | Buy | — |
| Aug 13, 2026 | Citizens | Market Outperform | — |
| Jul 13, 2026 | B. Riley Securities | Buy | — |
| Jun 16, 2026 | Guggenheim | Buy | — |
| Jun 9, 2026 | Jones Trading | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.